Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
The American Diabetes Association’s 85th Scientific Sessions provides the latest updates in diabetes research, prevention, and care. Key topics include the quality and accessibility of diabetes care, and technology innovations.
Once-weekly, fixed-dose insulin efsitora has been found noninferior to insulin glargine at reducing glycated hemoglobin levels in people with type 2 diabetes.
The long-acting peptide–antibody conjugate maridebart cafraglutide significantly reduces bodyweight versus placebo in people with obesity with or without type 2 diabetes.
Treatment with the cAMP-biased GLP-1 receptor agonist ecnoglutide results in clinically meaningful weight loss in adults with overweight and obesity but no diabetes, show data from the phase 3 SLIMMER study.
Combination treatment with cagrilintide and semaglutide significantly reduces bodyweight in adults living with overweight or obesity, with or without type 2 diabetes.
The single-molecule, dual GLP-1 and amylin receptor agonist amycretin shows promising tolerability and weight loss when given orally or subcutaneously to adults with overweight or obesity.
A round-up of the QWINT phase 3 clinical trials evaluating once-weekly insulin efsitora alfa in people with diabetes, including data simultaneously published and presented at the ADA's 85th Scientific Sessions.
We talk with Prof. Daniel Drucker about the early work on GLP-1 medicines for the treatment of diabetes, how they are now impacting the lives of people living with obesity, and their potential use for many other indications.
Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.
Dive into three expert-led programs detailing the latest updates on continuous glucose monitoring and continuous ketone monitoring to elevate care for your patients with diabetes.
